| Oct 31 |
Bristol-Myers raises outlook ahead of consensus after Q3 beat
|
| Oct 31 |
Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up
|
| Oct 31 |
Bristol Myers earnings beat expectations, driven by sales of older drugs
|
| Oct 31 |
Bristol Myers: Q3 Earnings Snapshot
|
| Oct 31 |
Bristol-Myers Squibb Company Non-GAAP EPS of $1.80 beats by $0.30, revenue of $11.89B beats by $640M
|
| Oct 31 |
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
|
| Oct 30 |
Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated
|
| Oct 30 |
Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is ‘Too Low’
|
| Oct 29 |
Zai Lab reports positive Chinese study data for KarXT for schizophrenia
|
| Oct 29 |
Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure
|
